In gliomas, the methylation status of the promoter for O6-methylguanine-DNA methyltransferase has been identified to associate with the progression of disease and to correlate with the sensitivity of glioma patients for TMZ treatment (65, 66). This evidence concerns the gene MGMT and central nervous system cancer.